SucroMate® Equine — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

SucroMate® Equine

Active ingredient

Deslorelin Acetate

Application type

NADA

Sponsor

Dechra Veterinary Products LLC

Applications on record

1

First published

July 14, 2026

Adverse event reports

Source: openFDA VeDDRA

390

Reports mentioning this ingredient

October 30, 1998 – January 23, 2026

40

Classified serious

per reporter assessment

69

Lack of expected efficacy

resistance signal

0

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “DESLORELIN ACETATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Implant, Abnormal	88
Lack of efficacy - NOS	51
Difficulty of Use	45
Lack of heat	36
Product defect, product difficult to use/handle (see also 'Drug device difficult to use/handle')	34
INEFFECTIVE, OVULATION	29
Applicator, Abnormal	24
Appearance, Abnormal	24
Administration device NOS, malfunction	24
Product syringe issue	20
Dispenser, Abnormal	16
Administration device NOS, abnormal	12
Abnormal oestrus NOS	10
Lack of hair regrowth	8
Implant, Damaged	8
Product Defect, General	7
Underfilling, Package	6
Containers, Damaged	5
Movement of implant	5
Death	5

Species affected

Source: openFDA VeDDRA

Ferret 89 Horse 80 Chicken 4 Cat 3 Dog 2 Rat 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient